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Abstract Russia has very high mortality from cardio-
vascular disease (CVD), with evidence that heavy drinking
may play a role. To throw further light on this association
we have studied the association of alcohol with predictors
of CVD risk including B-type natriuretic peptide (BNP).
Levels of BNP increase primarily in response to abnormal
cardiac chamber wall stretch which can occur both as a
result of atherosclerosis as well as due to other types of
damage to the myocardium. No previous population-based
studies have investigated the association with alcohol. We
analysed cross-sectional data on drinking behaviour in 993
men aged 25–60 years from the Izhevsk Family Study 2
(IFS2), conducted in the Russian city of Izhevsk in
2008–2009. Relative to non-drinkers, men who drank
hazardously had an odds ratio (OR) of being in the top
20 % of the BNP distribution of 4.66 (95 % CI 2.13, 10.19)
adjusted for age, obesity, waist–hip ratio, and smoking.
Further adjustment for class of hypertension resulted in
only slight attenuation of the effect, suggesting that this
effect was not secondary to the influence of alcohol on
blood pressure. In contrast hazardous drinking was asso-
ciated with markedly raised ApoA1 and HDL cholesterol
levels, but had little impact on levels of ApoB and LDL
cholesterol. Similar but less pronounced associations were
found in the Belfast (UK) component of the PRIME study
conducted in 1991. These findings suggest that the asso-
ciation of heavy drinking with increased risk of cardio-
vascular disease may be partly due to alcohol-induced
non-atherosclerotic damage to the myocardium.
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Introduction
B-type natriuretic peptide (BNP) levels are increased pri-
marily in response to abnormal cardiac chamber wall
stretch caused by increased haemodynamic load. This is
found in heart failure, as well as a result of damage to the
ventricle from cardiomyopathy, ischaemia or other causes
[1]. BNP levels are positively associated with risk of car-
diovascular events, in those initially free from cardiovas-
cular disease (CVD) [2, 3], without clinical evidence of
ventricular dysfunction [4], and at levels far below those
used in a clinical triage context to identify those with acute
heart failure [2, 5].
A considerable amount of work has been done on the
association of BNP levels with other cardiovascular risk
factors including smoking [6] and obesity [7]. In addition,
there is intriguing evidence that small, genetically deter-
mined life-long elevated levels of BNP protect against type
II diabetes mellitus, but are not associated with classic
cardio-metabolic risk factors including BMI, blood pres-
sure and lipid profiles [8]. However, surprisingly, the
association of BNP levels with alcohol consumption has
not been systematically investigated in population-based
studies. The only exception is a published table from the
British Regional Heart Study that indicates that ‘heavy
drinkers’ had raised NT-pro BNP levels, although this was
not commented upon in the text of the paper [9]. Aside
from this, the alcohol-BNP association has only been
investigated indirectly in a few small studies of patients
with alcoholic (and non-alcoholic) cirrhosis [10–12] and
oesophageal varices [13] that aimed to identify whether
this hormone could be used as a diagnostic/prognostic
marker. However, given continuing uncertainty about the
apparent cardio-protective effects of moderate drinking,
and increasing evidence that heavy drinking raises the risk
of ischaemic heart disease [14] and stroke [15, 16] this is a
major gap in the literature.
Russia has exceptionally high mortality from circulatory
disease, especially among working-age men, which is the
single main reason for their very low life expectancy at
birth (63 years in 2010). However, it has been repeatedly
noted that lipid profiles from Russian population samples
do not appear to be particularly pro-atherogenic: surpris-
ingly high HDL and ApoA1 levels, but unexceptional
levels of LDL and ApoB have been found in many studies
[17, 18]. In contrast control of blood pressure in Russia is
poor [19] and smoking rates among men are high [20].
Most recently, there is increasing evidence that in Russia
hazardous alcohol consumption is strongly associated with
deaths attributed to ischaemic heart disease [21–24]. This
could be due to alcohol promoting atherosclerosis or,
alternatively, could reflect misclassification of deaths due
to alcohol-induced damage to the myocardium causing
ventricular impairment and/or arrhythmias [25, 26] as
suggested almost two decades ago [17]. Little is known
about the mechanisms that may underlie these associations
of hazardous alcohol drinking with cardiovascular disease.
Here we report results of a study of working-age men in
the Russian city of Izhevsk in which we investigated
associations of alcohol consumption with BNP and other
predictors of cardiovascular risk including ApoA1 and
ApoB. Given the almost complete absence of published
data on the association of alcohol with BNP, we have
replicated the analysis using the Belfast (UK) component
of the PRIME study [27].
Methods
Izhevsk family study
The 2008–2009 Izhevsk Family Study 2 (IFS2) was a
cross-sectional survey of 1,531 working-age men
(25–60 years), 1,068 of whom had a medical examination.
Izhevsk is a typical medium-sized Russian city located on
the European side of the Urals. The participants were
originally recruited (2003–2006) as an age-stratified ran-
dom sample from the 2002 population register of adult city
residents [23].
Having traced the man to his current address in the city,
consent was sought to interview him and a proxy informant
(usually his wife or mother) living in the same household.
For those consenting, a trained interviewer collected
information from both a proxy informant and the man in
their own home using structured questionnaires in face-to-
face interviews.
For the purposes of these analyses we used information
provided by the man himself about socio-demographic char-
acteristics, smoking habits and also about the frequency of
drinking each type of beverage alcohol (beer, wine and spirits)
over the past year, and the amount of each beverage drunk on a
usual occasion. This latter information on alcohol consump-
tion was used to estimate the average volume of ethanol
consumed per week by each man, based on the assumption
that the concentration of ethanol by volume in beer was 4.5 %,
wine was 12 % and vodka and other spirits 43 %.
We also developed a measure of hazardous drinking that
was based on frequencies of various behaviours related to
either pattern of drinking or its consequences over the
preceding year. This included frequency of consumption of
non-beverage alcohols such as medicinal tinctures as well
as frequency of zapoi (a period of drunkenness of two or
more days characterised by withdrawal from normal social
life). Using this information we defined a hazardous
drinker as a man having one or more of the following
attributes: in the previous year any consumption of
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non-beverage alcohols, one or more episodes of zapoi, or
twice weekly or more occurrence of either hangover,
excessive drunkenness or going to sleep at night clothed
because of being drunk. As in our previous work, we
classified men as hazardous drinkers using proxy-reported
information on these aberrant, but easily observable
behaviours, as these were considered less likely to be
underestimated than self-reports [22, 23, 28].
A medical examination was offered to men following
the initial interview. Those men taking part in this second
stage provided information themselves in response to a
doctor-administered questionnaire. This included standard
questions on breathlessness and the Rose angina ques-
tionnaire. The distribution of men by age, drinking
behaviour and educational level was very similar regard-
less of whether or not they had a medical examination.
The majority (91 %) of the 1,068 examinations con-
ducted took place at a clinic, the remainder taking place in
the subject’s home. Hip and waist circumference, height
and weight were measured three times using standard
protocols and the mean of all three readings used in anal-
yses. Seated arterial blood pressure was measured three
times using Omron (705 IT) electronic sphygmomanome-
ters. The mean of the second and third readings were used
in the analyses. Non-fasting blood samples were taken.
These were placed in cool bags containing ice and trans-
ported to a local laboratory where they were spun in a
cooled centrifuge and aliquoted within 12 h of venepunc-
ture. Aliquots not used immediately were stored at -80 C.
Assays of GGT, Hepatitis B and C were conducted in
Izhevsk. GGT was measured using the kinetic colorimetric
method [29]. Hepatitis tests were carried out using kits
from Vector-Best [30]. Lipid and apolipoprotein assays
were conducted in Moscow using thawed samples by Ly-
tech, a commercial diagnostics laboratory using an Archi-
tect i2000 analyser. BNP was measured in EDTA plasma
using a chemiluminescent microparticle immunoassay
(CMIA) produced by Abbott for use on the Architect i2000
analyser. The alcohol biomarker, carbohydrate deficient
transferrin (CDT), was measured at the Moscow Research
and Practical Center on Addictions using the Sebia Cap-
illarys 2 multicapillary analyser [31].
Belfast PRIME study
The PRIME study is a multi-centre, prospective cohort
study of coronary events established in 1991 whose design
is described in detail elsewhere [27]. Briefly, the Belfast
component of the PRIME study (referred to simply as the
PRIME study hereafter) recruited men aged 50–59 years
who broadly matched the social class structure of this
Northern Irish city.
At baseline, 2,741 men completed self-administered
questionnaires at home that included questions on personal
and family history of disease, smoking, alcohol consump-
tion and physical activity. Alcohol consumption was
evaluated by assessing the different types of beverage
consumed (wine, beer, cider and spirits) and their alcohol
content (% alcohol by volume) for each day in the previous
week, or in a ‘‘usual’’ week if this was atypical. For each
day of the week, the numbers of standard servings (defined
explicitly in terms of amounts that respondents would
recognise) by beverage type and alcoholic strength were
recorded. This was converted into a total equivalent con-
sumption of pure ethanol for the entire week.
Height and weight were measured using a standard
protocol. Blood pressure was measured at the end of the
examination after a 5 min rest in the sitting position.
Measurements were performed with an automatic device
(Spengler SP9; Spengler, Asnie`res sur Seine, France). A
standard cuff size was used, but a larger cuff was available
when necessary. A fasting blood sample was drawn from
each participant, and the plasma was prepared with EDTA
and used for analysis of lipids. Plasma total cholesterol and
triglycerides were measured by enzymatic methods
using reagents from Boehringer Ingelheim (Mannheim,
Germany). Apolipoproteins A-1 and B were measured
by a nephelometric method (Behringwerke; Marburg,
Germany). GGT was measured using a Gamma-Glutamyl-
Transferase assay produced by Abbott for use on the
Architect c8000. As in IFS2, BNP was measured in EDTA
plasma using a chemiluminescent microparticle immuno-
assay (CMIA) produced by Abbott for use on the Architect
i2000. LDL levels were estimated using the Friedwald
equation in both IFS2 and the PRIME studies.
Exposure measures
Alcohol drinking was the primary exposure of interest, for
which we had three different measures. The exposure
available in both studies was self-reported average weekly
consumption of alcohol measured in units of 10 ml pure
ethanol derived as described above. For IFS2 we used a
second type of exposure measure which characterised
pattern of drinking based on proxy observations of fre-
quency of dysfunctional behaviours associated with heavy
drinking. This measure was constructed independent of
information about actual amount drunk, but has been
shown to be highly predictive of cardiovascular mortality
in an earlier study [22]. The third measure of exposure to
alcohol was more objective, being based on two alcohol
biomarkers (GGT and CDT) that were both only available
in IFS2. From these we derived a continuous normally
distributed biomarker variable that combined information
from GGT and CDT using a latent variable modeling
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approach. Our latent variable measurement model was
based on a multivariate logit analysis with latent variables
[32]. The measurement model was estimated in the Mplus
6.12 software, with the robust maximum likelihood esti-
mator (MLR) [33].
Outcome measures
The outcome measures were levels of BNP, other bio-
marker predictors of CVD risk and prevalence of hyper-
tension. All of the biomarkers were dichotomised
according to whether or not values fell into the top 20 %
(quintile) of the distribution of each study population. This
was done in preference to treating these outcomes as con-
tinuous variables for two reasons: (1) over 40 % of the BNP
levels in IFS2 fell below the limit of detection (10 pg/ml) and
using a cut-offs avoided this problem; (2) it allowed the
strength of associations of the alcohol variables with the
various outcomes to be directly compared without assump-
tions concerning the normality of their underlying distribu-
tion. Hypertension was treated as a binary variable.
Other covariates
In the regression models we adjusted for a number of other
covariates. Age was included in this category as an obvious
potential confounder, as was smoking. However, in addi-
tion we also adjusted for body mass index and waist–hip
ratio. Both of these markers of adiposity have been found
to be predictors of CHD risk, but both have in different
populations be associated with alcohol consumption.
However, as the focus of our analysis was on whether
alcohol per se might have a direct impact on cardiovascular
risk factors we adjusted for these markers of adiposity,
Table 1 Characteristics of IFS2 and PRIME study populations
Na Median or %
IFS2
(30–60 years)
IFS2
(50–60 years)b
PRIME
(50–60 years)
IFS2
(30–60 years)
IFS2
(50–60 years)b
PRIME
(50–60 years)
Age (years) 1,068 558 2,741 50 55 54
Waist–hip ratio 1,064 554 2,741 0.93 0.94 0.94
BMI (kg/m2) 1,060 551 2,741 25.9 25.8 26.0
Obese (C30 kg/m2) 1,060 551 2,741 18 % 18 % 12 %
Hypertensive (%) (SBP C 140 mmHg/
DBP C 90 mmHg)
1,061 553 2,738 59 % 69 % 40 %
Current smoker (%) 1,068 558 2,741 63 % 60 % 32 %
Units/week of beverage ethanol
consumed
1,051 551 2,741 8.5 6.7 8.3
Units/week of beverage ethanol
consumed (current drinkers)
915 474 2,101 11.1 10.1 15.9
Former drinkers 1,068 558 2,741 12.4 % 13.3 % 2.2 %
Life-long abstainers 1,068 558 2,741 0.8 % 0.5 % 21.1 %
BNP (pg/mL) 986 523 1,806 11.6 15.1 18.3
Total cholesterol (mmol/L) 981 504 2,733 5.32 5.37 5.85
HDL cholesterol (mmol/L) 981 504 2,733 1.34 1.34 1.16
LDL cholesterol (mmol/L) 963 494 2,679 3.20 3.23 3.89
Triglycerides (mmol/L) 963 494 2,734 1.28 1.29 1.50
Apolipoprotein A1 (g/L) 976 499 2,388 1.42 1.40 1.37
Apolipoprotein B (g/L) 977 500 2,389 0.88 0.90 1.14
Apolipoprotein B/Apolipoprotein
A1 ratio
976 499 2,387 0.62 0.64 0.84
Gamma glutamyl transferase
(GGT) (IU/L)
1,038 537 2,113 29.7 29.1 36.9
% Carbohydrate deficient transferrin
(CDT)
1,012 517 – 1.00 1.00 –
a For IFS2 subjects are all men who had been interviewed themselves and had attended the medical examination. For both studies variation in
numbers reflect missing information (including blood sample not available for analysis)
b To facilitate more direct comparison of characteristics of men in PRIME and IFS2, we have included this column that describes the subset of
IFS2 men who were in the same age range as the total PRIME population i.e. 50–60 years
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even though in some populations they might lie on the
causal pathway between alcohol and CVD risk.
Statistical methods
Logistic regression was used to estimate the strength of the
association of the the alcohol exposure variables with the
outcome biomarkers and hypertension. In these models
adjustment was made for BMI and waist–hip ratio in cat-
egories to avoid having to make assumptions about the
linearity of their associations with the outcomes. For the
BNP analyses in IFS2 we also checked that similar infer-
ences could be drawn from the results of tobit (censored)
regression. The IFS2 and PRIME analyses were conducted
using STATA 11 [34].
Ethical approval for IFS2 2 was granted by committees
of the Izhevsk State Medical Academy and the London
School of Hygiene & Tropical Medicine, and for the Bel-
fast PRIME study by Queens University Belfast. Partici-
pants in both studies gave informed consent compliant with
the guidelines of the Declaration of Helsinki.
Results
Table 1 shows the characteristics of the two study popu-
lations. Summary measures for IFS2 are presented for
those aged 50–60 years, as well as the total (aged
30–60 years), to allow direct comparison with the PRIME
population all of whom were in the age range 50–60 years.
Median BMI was very similar in the two studies. However,
the percentage obese was higher in IFS2, as were the
percentages of smokers and hypertensives. The average
number of units of alcohol reported to be consumed per
week was higher in PRIME than IFS2. However among
drinkers the mean percentage of beverage ethanol con-
sumed as spirits was 59 % in IFS2 but only 24 % in
PRIME. In addition, total ethanol consumption in IFS2 was
underestimated as it was not possible to take into account
ethanol from non-beverage sources, consumed by 7 % of
men in the previous year. The percentage of abstainers in
IFS2 was much lower than in PRIME (14 vs. 23 %)
although of these, nearly all were ex-drinkers in IFS2,
while in PRIME they were mostly life-long abstainers. The
lipid profile in the PRIME study was appreciably more pro-
atherogenic than in IFS2, with Belfast men having higher
LDL cholesterol, triglycerides, ApoB and ApoB/ApoA1
ratio (driven mainly by much higher ApoB), while Izhevsk
men had higher HDL levels.
The face-validity of the questionnaire-derived data on
alcohol drinking was confirmed in that there were strong,
graded associations of the alcohol biomarkers with volume
and pattern of drinking (Table 5).
In IFS2 those in the top quintile of the BNP distribution
had a BNP value of 27 pg/ml or more, the equivalent value
for the PRIME study being 34 pg/ml. Table 2 shows the
associations of various factors with being in the top quintile
of the BNP distribution in each study. Age was positively
associated with raised BNP levels in both studies, as was
class of hypertension and self-reports of breathlessness
when walking on level ground. However, Rose question-
naire reported angina was only associated with raised BNP
levels in PRIME, while smoking only showed an associa-
tion in IFS2. Class of obesity was not related with raised
BNP in either study.
Table 3 shows the association of various markers of
alcohol consumption with the risk of hypertension and
being in the top (study-specific) quintiles of various car-
diovascular biomarkers, adjusted for age, obesity and
waist–hip ratio. Adjustment for anthropometric variables
was undertaken as they may confound associations of
drinking behaviour and outcomes. However, this is a
conservative strategy, as it will also largely remove the
effects of alcohol on the outcomes that are mediated
through body habitus.
Strong positive associations were seen for all alcohol
variables in both studies with hypertension, raised HDL,
ApoA1 and BNP (Table 3), for all men and also among
drinkers. Of the other CVD risk factors, only triglycerides
showed a systematic association with alcohol, but this was
only seen for units of alcohol in the PRIME study.
With respect to BNP, the associations observed with the
alcohol variables could be (1) confounded by smoking; and/
or (2) mediated through the effects of alcohol on blood
pressure. These possibilities are examined in Table 4, where
the associations of alcohol with raised BNP levels are
adjusted for these covariates sequentially. In both popula-
tions, the risk of being in the top fifth of the BNP distribution
increased with level or intensity of alcohol consumption
regardless of which adjustments are made. In the PRIME
study, adjustment had minimal impact on strength of asso-
ciations, while in IFS2 adjustment attenuated the associa-
tions slightly more. Nevertheless, even in the fully adjusted
models the effects were substantial in IFS2, those with a low
average intake (\5 units/week) having a considerably
higher risk of raised BNP compared to non-drinkers. Most
strikingly, in the fully adjusted model in IFS2, hazardous
drinkers relative to non-drinkers had a four-fold increased
odds of being in the top fifth of the BNP distribution.
Sensitivity analyses were undertaken (results not shown).
In IFS2, adjustment for SBP and DBP as continuous vari-
ables instead of class of hypertension had no substantive
effect on the findings. In addition using tobit instead of
logistic regression, which allowed BNP to be treated as a
continuous left-censored variable, revealed very similar
effects, as did exclusion of men with angina. Analyses in
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PRIME excluding those with diagnosed cardiovascular
disease at baseline also produced very similar results.
Discussion
We have found that among working-age men heavy and
hazardous drinking is associated with elevated levels of
B-type natriuretic peptide in two population-based cross-
sectional studies in Russia and the UK. This is the first time
this association has been systematically investigated. These
associations displayed dose–response effects overall and
also when abstainers were excluded.
Alcohol and blood pressure are known to be positively
associated [35], and binge drinking has been found to be
associated with increased risk of stroke [16]. Blood
pressure is thus an obvious potential mediator of what we
have observed. Surprisingly, however, adjustment for class
of hypertension (as well as SBP and DBP in IFS2), resulted
in only minor attenuation of the strength of association of
alcohol with BNP. Of course the information we have on
blood pressure and hypertension is from one examination,
and as such will not fully reflect long term differences in
blood pressure. However, if blood pressure did play a
major mediating role, one would expect a larger degree of
attenuation.
As noted in the introduction, BNP levels may be raised
as a consequence of cardiac damage caused by athero-
sclerotic disease. However, exclusion of men with evi-
dence of pre-existing ischaemic heart disease or angina had
little impact on the results. Unfortunately, we did not have
any more direct measures of atherosclerotic disease which
Table 2 Association of BNP
with selected characteristics in
IFS2 and PRIME, adjusted for
age
OR—odds ratio of being in the
top 20 % of BNP distribution
For IFS2 subjects are all men
who had been interviewed
themselves and had attended the
medical examination. For both
studies variation in total
numbers reflect missing
information
Obesity class BMI
ranges = Underweight (B18.5);
Normal weight (C18.5–24.9);
Over weight (C25–29.9); Obese
(C30–34.9); Severely obese
(C35)
Hypertension = Mild SBP
140–159 or DBP 90–99;
Moderate 160–179 or 100–109;
Severe 180? or 110?
Stop for breath walking based
on response to question ‘‘Do
you have to stop for breath
when walking at your own pace
on level ground?’’
IFS2 PRIME
N OR (95 % CI) N OR (95 % CI)
Age (years)
\35 81 0.27 (0.10, 0.69) – – –
35–39 86 0.25 (0.10, 0.65) – – –
40–44 105 0.33 (0.15, 0.73) – – –
45–49 191 0.88 (0.54, 1.42) – – –
50–54 247 1.00 [ref] 1,006 1.00 [ref]
55–60 276 2.12 (1.42, 3.16) 800 1.89 (1.50, 2.39)
P value trend \0.001 –
Smoking
Never smoker 192 1.00 [ref] 614 1.00 [ref]
Former smoker 179 1.19 (0.67, 2.14) 688 1.00 (0.76, 1.32)
Current smoker 614 1.91 (1.20, 3.06) 504 0.95 (0.71, 1.29)
P value trend 0.002 0.796
Obesity class
Underweight 19 0.38 (0.08, 1.76) 5 – –
Normal weight 395 1.00 [ref] 661 1.00 [ref]
Over weight 386 0.77 (0.53, 1.10) 922 0.97 (0.75, 1.24)
Obese 142 0.61 (0.36, 1.04) 180 1.07 (0.71, 1.61)
Severely obese 38 0.65 (0.25, 1.67) 38 1.42 (0.67, 3.03)
P value trend 0.104 0.620
Hypertension
Normotensive 407 1.00 [ref] 1,092 1.00 [ref]
Mild hypertension 309 1.00 (0.66, 1.52) 456 1.04 (0.78, 1.38)
Moderate hypertension 163 1.35 (0.85, 2.15) 178 1.76 (1.22, 2.52)
Severe hypertension 103 2.45 (1.48, 4.05) 78 1.70 (1.01, 2.85)
P value trend 0.001 0.001
Angina (Rose questionnaire)
No 893 1.00 [ref] 1,643 1.00 [ref]
Yes 83 1.44 (0.95, 2.19) 163 2.77 (1.97, 3.90)
Stop for breath walking
No 934 1.00 [ref] 1,188 1.00 [ref]
Yes 44 2.37 (1.25, 4.52) 139 2.47 (1.66, 3.66)
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would have provided an even stronger base for assessing
whether the association is driven by the effect of heavy
drinking on coronary atherosclerosis. But in terms of
lipoproteins, there was no evidence in our analyses that
heavy and hazardous drinking was linked to a proathero-
genic profile. There was no consistent indication that LDL
and ApoB levels were elevated among heavy or hazardous
drinkers, in line with the findings of a recent review of
human experimental studies of the impact of alcohol on
cardiovascular risk factors [36]. However, it should be
noted that in the Belfast UK study, but not in Russia, there
was a positive association of alcohol volume with elevated
triglycerides.
The strongest associations we observed in both the
Russian and the UK studies were between alcohol and
HDL and Apo A1. While this is not a novel finding [36,
37], it provides further validation of the alcohol data. These
effects are particularly strong in the IFS2 study in Russia,
where a steep and consistent increase in risk of raised HDL
and Apo A1 was seen as volume and intensity of drinking
went up. Much of the literature seeking to explain the
apparent protective effect of moderate alcohol consump-
tion cites HDL as a potential underlying mechanism [38,
39]. However, there is now accumulating evidence from
randomised trials and studies of genetic variants that con-
trary to what was inferred from observational studies [40],
increasing total HDL per se may not be cardioprotective
[41, 42]. Aside from this, however, it is worth noting that
the mechanisms linking alcohol to HDL and Apo A1
remain elusive and poorly understood.
The Izhevsk study population had a low-risk atherogenic
profile compared with the the Belfast PRIME study with
lower levels of LDL and triglycerides. This parallels the
findings from the Lipid Research Clinics studies in the
1980s which found similar contrasts between study sites in
Russia and the USA [43]. In addition, the strength of the
associations seen in Izhevsk with HDL and ApoA1 are
remarkable, and are considerably steeper than in PRIME.
There thus appears to be something distinctive about the
impact of patterns of alcohol consumption in Russia that
produce these effects that are not captured by volume of
beverage ethanol, as was concluded by another study of the
atypical lipid profiles found in Russia [44].
Our analyses show that, of the risk factors considered,
blood pressure and BNP are the only ones that appear to be
consistent with the finding from previous work that in
Russia that heavy and hazardous drinking is associated
with an increased risk of cardiovascular disease [22, 24].
Aside from any minor contribution via blood pressure,
alcohol could also lead to an increase in BNP levels as a
result of the toxic effects of ethanol or its metabolites on
the myocardium, with consequent effects on cardiac con-
tractile function, and ventricular wall stress. This may
induce subclinical disease on a continuum of alcohol-
induced end organ damage, at the extreme end of which is
the well recognised entity of alcoholic cardiomyopathy.
While the extent of cardiac contractile dysfunction may be
modest, we hypothesise that this damage coupled with high
peak alcohol levels (as is common in Russia) may pose a
risk of life-threatening (ventricular) tachycardia and sud-
den death. To a lesser extent, this phenomenon may also
occur among particularly heavy drinkers in PRIME and
elsewhere. However, direct evidence for this is currently
lacking.
The data we had and the analyses we undertook had a
number of limitations. The alcohol exposure measures in
PRIME were more limited than in IFS2. Moreover, even in
terms of units per week, which were available in both studies,
IFS2 used information relating to usual drinking over the past
year, while PRIME had a reference period of the previous
week. This may provide a partial explanation for the slightly
weaker associations of BNP in PRIME compared to IFS2. A
further lack of comparability was introduced by the fact that
whereas in PRIME fasting blood samples were used, in IFS2
non-fasting samples were collected. This may partly explain
the fact that there was pronounced gradient in triglycerides
with increasing level of alcohol intake only in PRIME. One
further limitation was the fact that we did not undertake more
detailed clinical examinations in IFS2 to ascertain the car-
diac status of the individuals. This would have been very
valuable, and would have allowed us to look in more detail at
whether the raised BNP levels associated with heavy alcohol
consumption were also related to structural or functional
cardiac abnormalities.
This paper also has several strengths. Firstly, having
established the association of alcohol with BNP levels in
the Russian study, we then replicated it in a larger study
from Northern Ireland. In IFS2 we had biomarkers of
alcohol consumption that showed the same pattern of
associations with BNP and other outcomes as seen using
the questionnaire data on alcohol. Thirdly, in both studies,
BNP level was associated with breathlessness, demon-
strating face validity. Finally, although BNP measurements
in the two studies were carried out in different laboratories,
their comparability is strengthened by the fact that they
used the same type of analytic platform.
Compared to most other European countries, the pattern of
alcohol consumption in Russia is particularly hazardous [45].
The Izhevsk study population reflected this, with 59 % of
beverage ethanol consumed being from spirits, and 8 % of
men reported to have a hangover or be excessively drunk once
a week or more often. In addition, 7 % of men were reported to
have drunk non-beverage alcohols in the previous year. These
are relatively pure and highly concentrated sources of alcohol
(typically 70–90 % ethanol by volume) that are cheap, readily
available [46–48], and have been associated with particularly
400 D. A. Leon et al.
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high mortality [23]. In contrast in PRIME only 24 % of eth-
anol was consumed as spirits, and there was no equivalent
consumption of non-beverage alcohols.
Our findings are consistent with those of earlier studies
that grappled with the paradoxical aspects of cardiovascular
disease in Russia. The Lipid Research Clinics studies found
that total IHD mortality in Russia showed only a very
shallow decline with increasing HDL [17]. However, the
risk of sudden cardiac death actually increased at higher
levels of HDL. This led the authors to suggest that some of
these sudden IHD deaths were misclassified alcoholic car-
diomyopathies. Early evidence of this pathology has been
linked to sudden death in an autopsy study in Russia [49].
If a significant proportion of the cardiac deaths attributed
to ischaemic heart disease in Russia are in fact caused by
alcohol-induced damage to cardiac structure and function,
this has important implications for the primary prevention
of cardiovascular disease at working ages. It suggests that
Table 4 Association of BNP with measures of alcohol consumption, adjusted for various factors
Model 1 Model 2 Model 3
N OR (95 % CI) OR (95 % CI) OR (95 % CI)
Izhevsk Family Study 2
Alcohol biomarker quartilesa (N = 958)
1 (bottom) 246 1.00 [ref] 1.00 [ref] 1.00 [ref]
2 240 1.09 (0.64, 1.86) 1.03 (0.60, 1.76) 1.02 (0.6, 1.75)
3 237 2.07 (1.25, 3.42) 1.86 (1.11, 3.1) 1.79 (1.06, 3.01)
4 (top) 235 2.22 (1.37, 3.62) 1.94 (1.18, 3.21) 1.77 (1.05, 2.97)
P value trend \0.001 0.001 0.008
Pattern of drinking (proxy report) (N = 843)
Non-drinkerb 120 1.00 [ref] 1.00 [ref] 1.00 [ref]
Non- hazardous 600 2.58 (1.29, 5.17) 2.75 (1.37, 5.55) 2.66 (1.32, 5.37)
Hazardous 123 4.90 (2.27, 10.6) 4.66 (2.13, 10.19) 4.16 (1.88, 9.19)
P value trend \0.001 \0.001 \0.001
P value trend in drinkers 0.006 0.026 0.061
Alcohol units/week (self-report)c (N = 915)
Non-drinkerb 126 1.00 [ref] 1.00 [ref] 1.00 [ref]
\5 217 1.63 (0.79, 3.35) 1.67 (0.81, 3.45) 1.67 (0.81, 3.46)
5–19 357 3.11 (1.60, 6.05) 2.99 (1.53, 5.83) 2.81 (1.43, 5.52)
20–44 151 2.84 (1.34, 5.99) 2.73 (1.29, 5.78) 2.46 (1.15, 5.26)
45? 64 3.02 (1.23, 7.39) 2.86 (1.16, 7.06) 2.58 (1.03, 6.45)
P value trend 0.001 0.002 0.007
P value trend in drinkers 0.043 0.092 0.212
Belfast PRIME study
Alcohol units/week (self-report) (N = 1,804)
Non-drinkerb 399 1.00 [ref] 1.00 [ref] 1.00 [ref]
\5 419 0.98 (0.68, 1.39) 0.98 (0.69, 1.40) 0.98 (0.69, 1.41)
5–19 379 0.92 (0.64, 1.33) 0.94 (0.65, 1.37) 0.94 (0.65, 1.37)
20–44 362 1.21 (0.85, 1.74) 1.25 (0.87, 1.81) 1.23 (0.85, 1.77)
45? 245 1.53 (1.04, 2.26) 1.60 (1.08, 2.38) 1.51 (1.01, 2.25)
P value trend 0.006 0.004 0.012
P value trend in drinkers 0.008 0.003 0.012
ORs are odds ratios of being hypertensive or in the top 20 % of BNP
Excludes 3 subjects in IFS2 with serum creatinine [177 mmol/L
Model 1 - Age ? obesity class (4 categories) plus waist–hip ratio (quintiles)
Model 2 - Model 1 ? smoking (as never, former, current 1–20, 20?)
Model 3 - Model 2 ? class of hypertension (4 categories)
a Adjusted for hepatitis B and C status
b Ex-drinkers plus lifelong abstainers combined
c Excludes men who drank non-beverage alcohols, as it was not possible to quantify the volume of ethanol from this source
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the future development of primary care cardiovascular
screening programmes will need to give particular attention
to drinking behaviour. Moreover, although the wider
adoption of statins and anti-hypertensives in primary pre-
vention may have an important role to play in reducing the
burden of cardiovascular disease in Russia, we speculate
that this may not have as big an impact as might be antic-
ipated on the basis of the experience in Western European
populations with lower prevalences of hazardous drinking.
The data we have analysed in this paper are restricted to
men from only two populations. Nevertheless, this evidence
leads us to hypothesise that the relatively common patterns of
hazardous alcohol drinking among Russian men may directly
induce damage to the myocardium, and as a result increase the
risk of cardiovascular death through impaired ventricular
function and associated arrhythmias. However, at the present
time evidence suitable for directly testing this is lacking, and
new research aimed at exploring the cardiovascular phenotype
and its correlates in heavy, spirit drinking populations such as
Russia and elsewhere is now required.
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